Researchers from bioAffinity Technologies, presented new findings today at the 2025 RNA Therapeutics Conference, highlighting a potential broad-spectrum cancer therapy based on RNA interference mechanisms.
The presentation, titled “Silencing CD320 and LRP2 by siRNAs selectively kills cancer cells: mechanistic enigmas,” detailed preclinical research showing that targeting two specific cell surface receptors, CD320 and LRP2, using small interfering RNAs (siRNAs) led to the death of cancer cells across multiple tumor types while sparing healthy cells. The approach is currently protected by U.S. Patent No. 12,305,171, with a corresponding patent grant recently issued in China.
According to the data shared, the dual suppression of CD320 and LRP2 appears to be highly effective in halting cancer cell proliferation, regardless of tumor mutation status. The research team is also exploring topical formulations aimed at treating skin cancers and other cutaneous neoplasms.
Dr. David Elzi, Vice President of Product Development at bioAffinity, presented the findings on behalf of the research team. “Our studies show that silencing the cell surface receptors CD320 and LRP2 using siRNAs selectively kills or halts the growth of cancer cells while leaving normal cells unaffected”
The study adds to growing interest in RNA-based therapeutics, a rapidly expanding field within oncology. These approaches aim to exploit the body’s natural RNA machinery to silence disease-causing genes or proteins with high precision. Targeting surface receptors with siRNAs, as shown in this research, could open new avenues for treating cancers with fewer off-target effects.